Key result
Supportive care to reduce pediatric TKI cardiotoxicity involves surveillance, prevention, cardiac meds, and cardio-oncology collaboration.
Why the study?
Tyrosine kinase inhibitors improve outcomes in pediatric cancers but cause acute and long-term cardiotoxicities, requiring supportive care management to mitigate cardiotoxic risk.
What supportive care management strategies are used to mitigate TKI-associated cardiotoxicity in pediatric cancer patients and survivors?
What supportive care management strategies are used to mitigate TKI-associated cardiotoxicity in pediatric cancer patients and survivors?
Five key supportive care categories were identified to help mitigate acute and long-term cardiotoxicities associated with TKI use in pediatric cancer patients.
Requires oncology-cardiology collaboration for children on TKIs; extends sparse pediatric evidence on surveillance and care transitions.
Background Advances in targeted cancer therapies have transformed the management of pediatric malignancies. Tyrosine kinase inhibitors (TKIs), a specific class of targeted agents, inhibit signaling pathways essential to cancer cell survival. TKIs have improved outcomes in specific pediatric cancers. However, TKIs are associated with acute and long-term cardiotoxicities. Supportive care management aimed at prevention, early detection, and timely intervention is necessary to mitigate cardiotoxicity associated with TKIs. Method This rapid review examined the supportive care management used in children with cancer and childhood cancer survivors who received TKIs as part of their treatment. TKIs were selected due to their frequent use in pediatric oncology. Eligible studies, published between 2019 and 2025, included patients aged 0–21 years. From 206 citations, 30 duplicates were removed, and 176 records were screened in Rayyan. Fifteen full texts were reviewed, and two additional studies were hand-searched, yielding eight studies for inclusion. Data extraction, synthesis, and PRISMA documentation were completed collaboratively by the review team. Results Five key categories in supportive care management emerged: surveillance strategies, preventive strategies, cardiac medication use, collaboration between pediatric oncology and cardiology, and transition of care for childhood cancer survivors. Conclusion TKIs are associated with significant cardiotoxic risk in pediatric oncology. This review identified five supportive care categories that may inform future interdisciplinary research and guide the development of evidence-based supportive care recommendations aimed at optimizing cardiovascular outcomes in this patient population.
No takes yet. Share an insight, caveat, or question.
Fisher et al. (2026) studied this question. Supportive care for children receiving TKIs involves surveillance, prevention, cardiac meds, oncology-cardiology collaboration, and care transition to reduce cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: